Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours

Modlin, 1997, An analysis of 8305 cases of carcinoid tumors, Cancer, 79, 813, 10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2 Capella, 1995, Revised classification of neuroendocrine tumors of the lung, pancreas and gut, Virchows Arch (A), 425, 547 Mignon, 1986, Current approach to the management of tumoral process in patients with gastrinoma, World J. Surg., 10, 703, 10.1007/BF01655562 Godwin, 1980, Carcinoid tumors; an analysis of 2837 cases, Cancer, 45, 104 Zeitels, 1982, Carcinoid tumors, Arch. Surg., 117, 732, 10.1001/archsurg.1982.01380290176031 Moertel, 1987, An odyssey in the land of small tumors, J. Clin. Oncol., 5, 1503, 10.1200/JCO.1987.5.10.1502 Moertel, 1992, Streptozocin–doxorubicin, Streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma, N. Engl. J. Med., 326, 519, 10.1056/NEJM199202203260804 Moertel, 1991, Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin, Cancer, 68, 227, 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I Kvols, 1986, Treatment of the malignant carcinoid syndrome. Evaluation of a long acting somatostatin analogue, N. Engl. J. Med., 315, 663, 10.1056/NEJM198609113151102 Oberg, 1986, Treatment of malignant carcinoid tumors with human leukocyte interferon, Cancer Treat Rep., 70, 1297 Ruszniewski, 1993, Hepatic arterial chemoembolization in patients with liver metastases of neuroendocrine tumors. A prospective phase II study in 24 patients, Cancer, 71, 2624, 10.1002/1097-0142(19930415)71:8<2624::AID-CNCR2820710830>3.0.CO;2-B Madeira, 1998, Prognostic factors in patients with endocrine tumours of the duodenopancreatic area, Gut, 43, 422, 10.1136/gut.43.3.422 Reubi, 1994, Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNAs in primary human tumors using in situ hybridization, Cancer Res., 54, 3455 Davis, 1973, The malignant carcinoid syndrome, Surg. Gynecol. Obstet., 137, 628 Ruszniewski, 1996, Treatment of the carcinoid syndrome with long acting somatostatin analogue lanreotide, Gut, 39, 279, 10.1136/gut.39.2.279 Arnold, 1996, Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors, Gut, 38, 430, 10.1136/gut.38.3.430 Saltz, 1993, Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors, Cancer, 72, 244, 10.1002/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q Eriksson, 1997, High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumor, Ann. Oncol., 8, 1041, 10.1023/A:1008205415035 O'Toole, 2000, Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance, Cancer, 88, 770, 10.1002/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0 Tiensuu Janson, 1994, [111In-DTPA-d-Phe]octreotide scintigraphy in patients with carcinoid tumors, Eur. J. Endocrinol., 131, 577, 10.1530/eje.0.1310577 Mitry, 1999, Treatement of poorly-differentiated neuroendocrine tumours with etoposide and cisplatin, Br. J. Cancer, 81, 1351, 10.1038/sj.bjc.6690325 Reubi, 1990, Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas, Cancer Res., 50, 5969 Eriksson, 1990, Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors, Cancer, 65, 1883, 10.1002/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3 Faiss, 1998, Evaluation of the antiproliferative effect of lanreotide or interferon-alpha or the combination of both in the therapy of metastatic neuroendocrine tumors, Gastroenterology, 114, A59, 10.1016/S0016-5085(98)82418-9